Composite versus individual biomarkers for predicting clinical benefit to PD-1 blockade in NSCLC 105 3 17. Sholl, L.M. et al. The Promises and Challenges of Tumor Mutation Burden as an Immunotherapy Biomarker: A Perspective from the International Association for the Study of Lung Cancer Pathology Committee. J Thorac Oncol. 2020;15(9):1409–24. 18. Tumeh, P.C. et al. PD-1 blockade induces responses by inhibiting adaptive immune resistance. Nature. 2014;515(7528):568–71. 19. van der Leun, A.M., Thommen, D.S., Schumacher, T.N. CD8+ T cell states in human cancer: insights from single-cell analysis. Nat Rev Cancer. 2020;20(4):218–32. 20. Huang, A.C. et al. T-cell invigoration to tumour burden ratio associated with anti-PD-1 response. Nature. 2017;545(7652):60–5. 21. Le, D.T. et al. PD-1 Blockade in Tumors with Mismatch-Repair Deficiency. N Engl J Med. 2015;372(26):2509–20. 22. Fumet, J.D. et al. Prognostic and predictive role of CD8 and PD-L1 determination in lung tumor tissue of patients under anti-PD-1 therapy. Br J Cancer. 2018;119(8):950–60. 23. Hu-Lieskovan, S. et al. Tumor characteristics associated with benefit from pembrolizumab in advanced non–small cell lung cancer. Clin Cancer Res. 2019;25(16):5061–8. 24. Thommen, D.S. et al. A transcriptionally and functionally distinct PD-1+ CD8+ T cell pool with predictive potential in non-small-cell lung cancer treated with PD-1 blockade. Nat Med. 2018;24(7). 25. Hummelink, K. et al. PD-1T TILs as a predictive biomarker for clinical benefit to PD-1 blockade in patients with advanced NSCLC. Clin Cancer Res. 2022;(10):1–14. 26. Cabrita, R. et al. Tertiary lymphoid structures improve immunotherapy and survival in melanoma. Nature. 2020;(February). 27. Helmink, B.A. et al. B cells and tertiary lymphoid structures promote immunotherapy response. Nature. 2020;(February). 28. Petitprez, F. et al. B cells are associated with survival and immunotherapy response in sarcoma. Nature. 2020;577(June 2018). 29. Ayers, M. et al. IFN- γ – related mRNA profile predicts clinical response to PD-1 blockade. J Clin Invest. 2017;127(8):2930–40. 30. Fehrenbacher, L. et al. Atezolizumab versus docetaxel for patients with previously treated non-small-cell lung cancer (POPLAR): A multicentre, open-label, phase 2 randomised controlled trial. Lancet. 2016;387(10030):1837–46. 31. Higgs, B.W. et al. Interferon gamma messenger RNA Signature in tumor biopsies predicts outcomes in patients with non–small cell lung carcinoma or urothelial cancer treated with durvalumab. Clin Cancer Res. 2018;24(16):3857–66. 32. Rizvi, H. et al. Molecular determinants of response to anti-programmed cell death (PD)-1 and anti-programmed death-ligand 1 (PD-L1) blockade in patients with non-small-cell lung cancer profiled with targeted next-generation sequencing. J Clin Oncol. 2018;36(7):633–41. 33. Hellmann, M.D. et al. Genomic Features of Response to Combination Immunotherapy in Patients with Advanced Non-Small-Cell Lung Cancer. Cancer Cell. 2018;33(5):843-852.e4. 34. Althammer, S. et al. Automated image analysis of NSCLC biopsies to predict response to anti-PD-L1 therapy. J Immunother Cancer. 2019;7(1):1–12. 35. Hummelink, K. et al. A dysfunctional T-cell gene signature for predicting nonresponse to PD-1 blockade in non-small cell lung cancer that is suitable for routine clinical diagnostics. Clin Cancer Res. 2024 Feb 16;30(4):814-823.
RkJQdWJsaXNoZXIy MTk4NDMw